We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why 2025 is a Dynamic and Transformative Year for Collegium
Read MoreHide Full Article
Key Takeaways
Collegium advanced with major buybacks, governance changes and expanded ADHD commercial efforts.
The company deployed about 180 reps for Jornay PM and continued disciplined capital allocation.
Collegium beat Q3 earnings and revenue estimates, extending its streak of topping consensus targets.
Collegium Pharmaceutical, Inc. (COLL - Free Report) has had a dynamic year, one defined by both strategic discipline and an unmistakable optimism about its future trajectory. The company, which is part of the Zacks Medical – Drugs industry, has leaned into its strengths, its pain-management franchise and its newer ADHD offering, Jornay PM, and is backing that vision with bold capital moves.
Share Buybacks Highlight Long-Term Confidence
A major signal of confidence has been the firm’s aggressive share buyback strategy. In May, Collegium struck a $25 million accelerated share repurchase (ASR) deal with Jefferies, and in July its board authorized a fresh $150 million repurchase program through the end of 2026. These steps underline a dual mandate, i.e., investing in growth, while returning capital to shareholders where possible.
Strengthening Governance and Commercial Expansion
Corporate governance is also evolving. Collegium has refreshed its board, naming Gino Santini as chairman and adding new director Nancy S. Lurker, as part of a longer-term succession and oversight strategy. At the same time, it is expanding its ADHD commercial operations. The company recently completed a field-force expansion for Jornay PM, deploying around 180 trained sales reps to push deeper into its neuropsychiatric business.
Underpinning all of this is Collegium’s disciplined capital allocation framework. It is paying down debt, engaging in opportunistic share repurchases and prioritizing business development in areas that promise durable long-term returns.
Collegium, a Zacks Rank #1 (Strong Buy) company, is no longer just a pain specialist. With Jornay PM gaining momentum, it is carving out a broader niche in neuropsychiatry. That said, in this space, it competes with companies like Amneal Pharmaceuticals, Inc. (AMRX - Free Report) , which also sells branded pain treatments, and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , making it critical for Collegium to maintain both innovation and operational strength. While ANIP also sports a Zacks Rank #1, AMRX currently carries a #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here. Shares of COLL, AMRX and ANIP have advanced 53.4%, 45.5% and 42% year to date as of Nov. 20.
Consistent Outperformance Reinforces Momentum
In the first week of November, Collegium came out with third-quarter 2025 adjusted earnings of $2.25/share, beating the Zacks Consensus Estimate of $1.88. This compares favorably with earnings of $1.61 per share a year ago. It also posted revenues of $209.36 million for the quarter, surpassing the Zacks Consensus Estimate of $189.73 million. This also compares favorably with year-ago revenues of $159.3 million. The company topped consensus revenue estimates in each of the last four quarters.
Bottom Line
All in all, 2025 has been a year of consolidation and strategic evolution for Collegium. Rather than relying on short-term gains, it seems positioned for sustainable, shareholder-focused growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why 2025 is a Dynamic and Transformative Year for Collegium
Key Takeaways
Collegium Pharmaceutical, Inc. (COLL - Free Report) has had a dynamic year, one defined by both strategic discipline and an unmistakable optimism about its future trajectory. The company, which is part of the Zacks Medical – Drugs industry, has leaned into its strengths, its pain-management franchise and its newer ADHD offering, Jornay PM, and is backing that vision with bold capital moves.
Share Buybacks Highlight Long-Term Confidence
A major signal of confidence has been the firm’s aggressive share buyback strategy. In May, Collegium struck a $25 million accelerated share repurchase (ASR) deal with Jefferies, and in July its board authorized a fresh $150 million repurchase program through the end of 2026. These steps underline a dual mandate, i.e., investing in growth, while returning capital to shareholders where possible.
Strengthening Governance and Commercial Expansion
Corporate governance is also evolving. Collegium has refreshed its board, naming Gino Santini as chairman and adding new director Nancy S. Lurker, as part of a longer-term succession and oversight strategy. At the same time, it is expanding its ADHD commercial operations. The company recently completed a field-force expansion for Jornay PM, deploying around 180 trained sales reps to push deeper into its neuropsychiatric business.
Underpinning all of this is Collegium’s disciplined capital allocation framework. It is paying down debt, engaging in opportunistic share repurchases and prioritizing business development in areas that promise durable long-term returns.
Broadening Beyond Pain Management Amid Competition
Collegium, a Zacks Rank #1 (Strong Buy) company, is no longer just a pain specialist. With Jornay PM gaining momentum, it is carving out a broader niche in neuropsychiatry. That said, in this space, it competes with companies like Amneal Pharmaceuticals, Inc. (AMRX - Free Report) , which also sells branded pain treatments, and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , making it critical for Collegium to maintain both innovation and operational strength. While ANIP also sports a Zacks Rank #1, AMRX currently carries a #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here. Shares of COLL, AMRX and ANIP have advanced 53.4%, 45.5% and 42% year to date as of Nov. 20.
Consistent Outperformance Reinforces Momentum
In the first week of November, Collegium came out with third-quarter 2025 adjusted earnings of $2.25/share, beating the Zacks Consensus Estimate of $1.88. This compares favorably with earnings of $1.61 per share a year ago. It also posted revenues of $209.36 million for the quarter, surpassing the Zacks Consensus Estimate of $189.73 million. This also compares favorably with year-ago revenues of $159.3 million. The company topped consensus revenue estimates in each of the last four quarters.
Bottom Line
All in all, 2025 has been a year of consolidation and strategic evolution for Collegium. Rather than relying on short-term gains, it seems positioned for sustainable, shareholder-focused growth.